I-Mab Reports Poster Presentation Highlighting Top-line Results From Its Ongoing Phase 1 Clinical Study Of Givastomig AT ESMO 2024
I-Mab Reports Poster Presentation Highlighting Top-line Results From Its Ongoing Phase 1 Clinical Study Of Givastomig AT ESMO 2024
天境生物報道了其正在進行的Givastomig臨床一期研究的頂線結果的海報展示在2024年ESMO大會上。
- Expanded Phase 1 monotherapy study of givastomig, a Claudin 18.2 X 4-1BB bispecific antibody immunostimulant, shows promising single-agent activity in heavily pre-treated patients with gastric cancers expressing Claudin 18.2 at low and high levels.
- The recommended Phase 2 dose for givastomig was determined to be 8-12 mg/kg; givastomig was well tolerated up to the highest study doses
- Givastomig擴大的一期單藥研究顯示了在胃癌患者中,表達Claudin 18.2低水平和高水平的Givastomig具有潛在的單藥活性,這些患者已接受了重度預處理。
- 推薦的Givastomig二期劑量確定爲8-12毫克/千克;Givastomig在最高研究劑量下耐受性良好。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。